He published many articles in the KES Journal and likely involved with Belviq's approval.
Hong-Kyu Lee is Director of the Institute of Endocrinology,
Nutrition and Metabolism at the Research Institute of Medicine,
Seoul National University, Republic of Korea, and Chief of the
Division of Endocrinology and Metabolism, Seoul National
University Hospital. He obtained his MD from Seoul National
University Medical College in 1968 and received board certification
in Internal Medicine in 1973.
Professor Lee also served as a special advisor to the Minister of
Health and Welfare in the Republic of Korea and is a member
of the World Health Organization expert panel on Chronic
Degenerative Diseases. He is currently involved with several
scientific organizations in Korea, including the Korean Medical
Association, the Korean Diabetes Association and the Korean
Society for Nutritional Medicine, for which he is currently serving as
President. Internationally, Professor Lee is founding President of
the Asian Society for Mitochondrial Research and Medicine, and
Vice President of the International Diabetes Epidemiology Group.
His career has included a research position in the US. At present,
Professor Lee’s major research interests include the pathogenesis
of diabetes and the metabolic syndrome through mitochondrial
mechanisms with a focus on environmental factors and
bioenergetics, the complex system approach to medicine.
He has authored or co-authored over 200 scientific articles and
abstracts in Korean and English language journals and has written
He is legit..
data suggest is could be
go check it out.
We will soon know.
What the H*LL is this!!!!
Prognostic Value of Remnant-Like Lipoprotein
Particle Levels in Patients With Coronary
Artery Disease and Type II Diabetes Mellitus
Hironobu Fukushima, MD,* Seigo Sugiyama, MD, PHD,* Osamu Honda, MD,* Shunichi Koide, MD,*
Shinichi Nakamura, MD,* Tomohiro Sakamoto, MD, PHD,* Michihiro Yoshimura, MD, PHD,*
Hisao Ogawa, MD, PHD,* Daisuke Fujioka, MD,† Kiyotaka Kugiyama, MD, PHD†
Yamanashi and Kumamoto, Japan
OBJECTIVES This study prospectively examined whether the levels of high remnant-like lipoprotein
particles (RLP) cholesterol have a significant risk and influence prognosis in patients with
coronary artery disease (CAD) and type II diabetes mellitus (DM).
BACKGROUND Several studies have shown that triglyceride-rich lipoproteins contribute to atherosclerotic
complications in type II DM. However, it remains to be established which triglyceride-rich
lipoproteins contribute to this risk.
METHODS Levels of RLP cholesterol in fasting serum were measured by an immunoseparation method
in 240 type II DM patients with (n _ 120) or without (n _ 120) CAD. The patients with
CAD were followed up for a period of _24 months until the occurrence of one of the
following clinical coronary events: re-admission or coronary revascularization due to recurrent
or refractory angina pectoris, nonfatal myocardial infarction, or cardiac death.
RESULTS Patients with CAD had higher RLP levels than patients without CAD. Multivariate logistic
regression analysis showed that high RLP cholesterol levels (_4.7 mg cholesterol/dl,
representing the 75th percentile of the distribution of RLP cholesterol levels in control
subjects) were a significant risk factor for the presence of CAD, independent of traditional
risk factors. Kaplan-Meier analysis demonstrated that higher RLP cholesterol levels in
patients with CAD resulted in a significantly higher probability for the development of
coronary events. Multivariate Cox hazards analysis showed that high RLP cholesterol levels
in patients with CAD were a significant predictor of future coronary events, independent of
other risk factors.
CONCLUSIONS Increased levels of RLP cholesterol are a significant and independent risk factor of CAD and
predict future coronary events in patients with CAD and type II DM. (J Am Coll Cardiol
2004;43:2219 –24) © 2004 by the American College of Cardiology Foundation